Molecular Mechanisms of Biomolecular Condensate Remodeling During Cellular Stress

Abstract

Biomolecular condensates, dynamic membraneless organelles formed via liquid-liquid phase separation, play pivotal roles in cellular organization and stress responses. Their remodeling under stress conditions has profound implications for cell survival, adaptation, and disease pathogenesis. This review synthesizes current understanding of the molecular mechanisms governing condensate remodeling during cellular stress, integrating recent research, clinical insights, and guideline-based perspectives to inform healthcare professionals about the translational significance of condensate dynamics in health and disease.

Introduction

Cellular stress responses are tightly regulated processes that determine cell fate under adverse conditions such as heat shock, oxidative injury, or nutrient deprivation. Biomolecular condensates, including stress granules (SGs), nucleoli, and P-bodies, are increasingly recognized as critical players in these responses. Their rapid assembly, disassembly, and compositional remodeling enable cells to adapt to fluctuating environments. Emerging evidence links aberrant condensate dynamics to neurodegeneration, cancer, and other pathologies, highlighting the need for a mechanistic understanding of condensate remodeling under stress for clinical translation.

Epidemiology / Disease Burden

The dysregulation of biomolecular condensate dynamics has been implicated in a spectrum of diseases, notably neurodegenerative disorders such as amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), and certain malignancies. Approximately 10% of ALS cases show pathogenic mutations in RNA-binding proteins that influence stress granule assembly. Similarly, condensate abnormalities are prevalent in Alzheimer’s, Parkinson’s, and various myopathies. The disease burden associated with defective condensate remodeling is substantial, underscoring its relevance to both global health and clinical practice.

Pathophysiology

Under normal conditions, biomolecular condensates form via reversible, weak multivalent interactions among proteins and nucleic acids, creating dynamic microenvironments for biochemical reactions. Stress triggers molecular changes—such as phosphorylation, ubiquitination, and changes in RNA content—that modulate the physical state and composition of condensates. For example, phosphorylation of RNA-binding proteins like TDP-43 or FUS can alter their phase behavior, leading to persistent or aberrant condensates. These changes can either support adaptive survival pathways (by sequestering pro-apoptotic factors) or, if dysregulated, drive aggregation and cytotoxicity, as seen in proteinopathies and cancer cell survival mechanisms.

Risk Factors

Genetic mutations in genes encoding low-complexity domain (LCD) proteins (e.g., FUS, hnRNPA1, TDP-43), disruptions in post-translational modification enzymes, and chronic cellular stressors (such as oxidative stress, hypoxia, and metabolic dysregulation) increase susceptibility to condensate remodeling defects. Environmental toxins, aging, and persistent inflammation further exacerbate risk by promoting maladaptive condensate transitions and pathological aggregation.

Clinical Features

Clinically, aberrant condensate remodeling manifests as progressive neurological decline in ALS and FTD, with pathognomonic cytoplasmic inclusions of TDP-43 or FUS in affected neurons. In oncological contexts, altered condensate dynamics contribute to chemotherapy resistance, stemness, and metastatic potential. Muscle disorders, cardiac dysfunction, and certain autoimmune phenotypes may also result from defective stress granule dynamics or nucleolar organization, reflecting the wide-ranging clinical impact of condensate pathology.

Diagnosis

Current diagnostic approaches to condensate-related diseases rely on histopathological analysis of tissue biopsies, immunohistochemistry for condensate markers (e.g., TDP-43, FUS), and advanced imaging modalities such as super-resolution microscopy. Molecular assays detecting mutations in condensate-associated genes, along with in vitro phase separation assays, are increasingly used in research settings. Biomarkers reflecting condensate dysregulation (e.g., altered RNA profiles or mislocalized proteins in CSF) offer promise for earlier and more precise diagnosis.

Treatment & Management

Management of diseases linked to condensate remodeling remains challenging. Supportive care and symptomatic therapies predominate in neurodegenerative diseases. Disease-modifying strategies under investigation include small molecules targeting phase behavior, antisense oligonucleotides to modulate RNA-protein interactions, and agents enhancing proteostasis. In oncology, targeting condensate-driven transcriptional programs or disrupting pathological condensate assembly is an emerging therapeutic frontier.

Recent Advances / Emerging Therapies

Recent advances have elucidated key molecular switches regulating condensate dynamics, such as kinases (e.g., DYRK3, GSK3β), chaperones (HSP70, HSPB8), and RNA modifications (N6-methyladenosine). Small molecules modulating these pathways—such as metformin (activating AMP-activated protein kinase) or phase-separating inhibitors—have demonstrated efficacy in preclinical models. CRISPR-based screens are uncovering new condensate regulators, while biomimetic peptides and engineered protein domains offer novel ways to manipulate condensate behavior therapeutically.

Guideline Recommendations

While formal clinical guidelines for condensate-targeting therapies are not yet established, expert consensus emphasizes the importance of early genetic screening in at-risk populations, robust neuropathological characterization, and multidisciplinary management. For neurodegenerative disorders, integrating molecular diagnostics with traditional clinical criteria is recommended. In oncology, ongoing trials may soon inform guideline development for condensate-modulating agents. Continued research and real-time evidence synthesis are essential to inform best practices.

Conclusion

Understanding the molecular mechanisms of biomolecular condensate remodeling during cellular stress has profound clinical and scientific implications. Advances in this field are rapidly redefining how we conceptualize and treat diseases characterized by condensate dysregulation. Ongoing research promises not only to elucidate the fundamental biology of stress responses but also to translate these insights into innovative diagnostics and therapeutics for a range of currently intractable diseases.